Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Genetics announced that its lead asset FID-007, in combination with cetuximab, will be presented in the Rapid Oral Abstract Session at the ASCO 2026 Annual Meeting on June 1, 2026. Interim Phase 2 data showed a 60% objective response rate (ORR) and 7.2-month median progression-free survival in patients with recurrent or metastatic head and neck squamous cell carcinoma, significantly outperforming the historical standard of care ORR of 5.8% to 19.1%.
Key figures
- Drug Name
- FID-007
- Phase Of Trial
- Phase 2
- Orr
- 60%
- Median dor
- 7.4 months
- Median pfs
- 7.2 months
- Evaluable patients
- 42
- Historical orr range
- 5.8% to 19.1%
- Historical pfs range
- 2.3 to 3.7 months
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.